Cisen Pharmaceutical Ltd.

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation, levamlodipine besylate tablets (5 mg, manufactured by Chenxin Pharmaceutical Co., Ltd.), and the reference formulation, amlodipine besylate tablets (Norvasc®, 10 mg, manufactured by Huizhi Pharmaceutical (Dalian) Co., Ltd.), in healthy trial participants under fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting and postprandial conditions. Secondary objective: To evaluate the safety of the test formulation, levamlodipine besylate tablets (5 mg), and the reference formulation, amlodipine besylate tablets (Norvasc®, 10 mg), in healthy trial participants.

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation, eperisone hydrochloride tablets (50 mg, manufactured by Chenxin Pharmaceutical Co., Ltd.), and the reference formulation, eperisone hydrochloride tablets (Miaona®, 50 mg, certified by Eisai (China) Pharmaceutical Co., Ltd.), in healthy adult participants under both fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting and postprandial conditions. Secondary objective: To evaluate the safety of the test formulation, eperisone hydrochloride tablets (50 mg), and the reference formulation, eperisone hydrochloride tablets (Miaona®, 50 mg), in healthy adult participants.

Primary objective: To evaluate the pharmacokinetics of baricitinib tablets (4 mg, developed by Chenxin Pharmaceutical Co., Ltd.) in healthy participants and assess the bioequivalence of the two formulations after a meal, using baricitinib tablets (trade name: Olumiant®, 4 mg, certified by Iriirily Co., Ltd., Japan) as the test formulation. Secondary objective: To evaluate the safety of a single postprandial oral administration of the test and reference formulations of baricitinib tablets in healthy Chinese participants.